Loading organizations...
Biofidelity is a genomic technology company based in Cambridge, England, with a United States headquarters in North Carolina, that develops simplified molecular diagnostic tools to make precision medicine and oncology testing more accessible. The organization provides proprietary diagnostic testing kits, such as the ASPYRE-Lung panel, which allow clinical laboratories to perform rapid, highly sensitive genomic profiling without requiring complex next-generation sequencing equipment. Operating with a global workforce of 62 employees, the enterprise has secured over $50 million in total venture funding to date, which includes a $24 million Series A+ financing round completed in February 2022. Biofidelity is financially backed by a syndicate of prominent institutional venture capital firms and strategic corporate partners, including Agilent Technologies, BlueYard Capital, and Octopus Ventures. The clinical diagnostics company was officially founded in 2019 by Barnaby Balmforth and Cameron Frayling.
Biofidelity has raised $59.0M across 3 funding rounds.
Biofidelity has raised $59.0M in total across 3 funding rounds.
Biofidelity has raised $59.0M in total across 3 funding rounds.
Biofidelity's investors include Tad Weems, BlueYard Capital, Longwall Ventures, Octopus Ventures, Jonathan Milner, Matthew Frohn, SBI Investment, Ciarán O'Leary, Agilent Technologies.
Biofidelity has raised $59.0M across 3 funding rounds. Most recently, it raised $24.0M Other Equity in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 3, 2024 | $24M Venture Round | — | TAD Weems, BlueYard Capital, Longwall Ventures, Octopus Ventures | Announced |
| Jan 1, 2022 | $23M Series A | Octopus Ventures | Jonathan Milner, Matthew Frohn, SBI Investment | Announced |
| Aug 20, 2020 | $12M Series A | Ciarán O'Leary | Agilent Technologies, Longwall Ventures | Announced |
Biofidelity is a commercial-stage genomic technology company founded in 2019, specializing in innovative molecular tools that simplify and accelerate biomarker detection for cancer patients.[1][2][4] Its flagship products, Aspyre® and Enspyre®, target every stage of the cancer journey—from early detection and treatment selection to monitoring minimal residual disease—by removing uninformative DNA noise, enabling results in days at a fraction of traditional sequencing costs.[1][2] The company serves clinicians, patients, and biopharma through tests like ASPYRE®-Lung for non-small cell lung cancer biomarkers, addressing treatment resistance in oncology.[1][3] With operations in Cambridge, UK, and North Carolina, US, Biofidelity has raised $60 million from investors including Agilent Technologies, Octopus Ventures, and BlueYard Capital, fueling US expansion and clinical adoption.[1]
Biofidelity was co-founded in 2019 by Dr. Barnaby Balmforth (CEO) and Cameron Frayling, emerging from Cambridge, UK, as a biotech spinout focused on revolutionizing genomic analysis for oncology.[1][4][5] Balmforth, with a PhD, leads the firm in developing technology that eliminates barriers in DNA analysis for faster, cost-effective precision medicine.[1] The idea stemmed from the need to enhance early detection of treatment resistance, simplifying complex genomic testing that often delays patient care.[1][2] Early traction included product launches like ASPYRE®-Lung and a $24 million funding round in recent years, building to $60 million total and partnerships for global clinical trials.[1][3]
Biofidelity rides the precision oncology wave, where genomic insights drive targeted therapies amid rising cancer prevalence and demand for personalized medicine.[2][3] Its timing aligns with advances in biopharma trials needing rapid biomarker screening, as seen in the 2025 CellCarta partnership for global CRO integration.[3] Market forces like cost pressures on sequencing and regulatory pushes for efficient testing favor its simplified approach, influencing the ecosystem by lowering barriers for labs and speeding trial enrollment.[1][3] As a bridge between genomics innovation and clinical reality, Biofidelity expands access to therapies, potentially reshaping oncology workflows in the US and beyond.[1]
Biofidelity is poised for accelerated US commercialization of ASPYRE®-Lung and broader Aspyre®/Enspyre® rollout, bolstered by $60 million funding and strategic alliances like CellCarta.[1][3] Trends in AI-enhanced genomics and precision trial matching will amplify its edge, with potential for new indications beyond lung cancer. Its influence may evolve into a standard for simplified profiling, driving more patients to optimal treatments and solidifying its role in global oncology innovation—transforming complex cancer care into routine precision.
